Kamada Ltd (KMDA)

Etorro trading 970x250
Kamada Ltd (KMDA) Logo

About Kamada Ltd

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. Address: 2 Holzman Street, Rehovot, Israel, 7670402

Kamada Ltd News and around…

Latest news about Kamada Ltd (KMDA) common stock and company :

Kamada Stock Jumps After Acquisition Of Four Plasma-Derived Products
22 Nov, 2021 FinancialContent

Kamada Ltd(NASDAQ: KMDA) has acquired four FDA-approved plasma-derived hyperimmune commercial products fromSaol ...

Kamada: Q3 Earnings Insights
22 Nov, 2021 FinancialContent

Kamada (NASDAQ:KMDA) reported its Q3 earnings results on Monday, November 22, 2021 at 08:00 AM. Here's what investors ...

Kamada (KMDA) Reports Q3 Loss, Lags Revenue Estimates
22 Nov, 2021 Yahoo! Finance

Kamada (KMDA) delivered earnings and revenue surprises of -166.67% and 8.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products
22 Nov, 2021 Yahoo! Finance

2021 Global Revenue of the Portfolio Acquired from Saol Therapeutics is Estimated Between $40 Million to $45 Million, with Approximately 75% and 20% of Sales Generated from U.S. and Canada, Respectively Acquisition Advances Kamada's Strategy of Evolving Into a Fully-Integrated Specialty Plasma Company with Strong Commercial Capabilities in the U.S.; Kamada’s Wholly-Owned U.S. Subsidiary, Kamada Inc, will be Responsible for the Commercialization of the Products in the U.S. MarketTransaction is Im

Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products
22 Nov, 2021 Yahoo! Finance

Third Quarter 2021 Revenues were $23.0 Million and Total Revenues for the First Nine Months of 2021 were $72.2 MillionKamada has Acquired a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products from Saol Therapeutics; Transaction Supports Kamada's Strategy of Evolving into a Fully-Integrated Specialty Plasma Company with Strong Commercial Capabilities in the U.S. and Further Enhances Kamada's Global Leadership in Development, Manufacturing and Commercialization of Plasma-

Earnings Scheduled For November 22, 2021
22 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per ...

Kamada's Earnings: A Preview
19 Nov, 2021 FinancialContent

Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know ...

Kamada to Announce Third Quarter Financial Results and Host Conference Call on November 22, 2021
08 Nov, 2021 Yahoo! Finance

REHOVOT, Israel, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and nine months ended September 30, 2021, prior to the open of the U.S. financial markets on Monday, November 22, 2021. Kamada management will host an investment community conference call on Monday, November 22, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and ot

Bullish Two Hundred Day Moving Average Cross - KMDA
02 Nov, 2021 FinancialContent

In trading on Tuesday, shares of Kamada Ltd (KMDA) crossed above their 200 day moving average of $5.91, changing hands as high as $6.00 per share. Kamada Ltd shares are currently trading up about 1.7% on the day..

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Japan's Nikkei extends rally on Wall Street gains, Toyota lifts Topix
08 Oct, 2021 Yahoo! Finance

Japan's Nikkei rose for a second straight session on Friday, tracking gains on Wall Street and as investors scooped up bargains after sharp declines this month, while Toyota Motor helped the Topix close higher for the first time in 10 sessions. The Nikkei share average ended 1.34% higher at 28,048.94, paring gains after a 2.3% jump in early trade as investors awaited industry bellwether Yaskawa Electric to kick off the earnings season later in the day. For the week, the Nikkei dropped 2.51%, weighed down by concerns about China's economic slowdown and U.S. inflation fears.

Japanese shares track Wall Street higher, Toyota lifts Topix
08 Oct, 2021 Yahoo! Finance

Japan's Nikkei share average jumped on Friday, tracking gains on Wall Street and as investors scooped up bargains after sharp declines this month, while Toyota Motor helped the Topix trade higher after nine straight sessions of falls. Wall Street ended sharply higher overnight in a broad-based rally led by Big Tech, as a truce in the debt-ceiling standoff in the Congress relieved concerns of a possible government debt default this month. "Domestic shares rose because overseas markets advanced, but today's gain was just a rebound from sharp losses," said Shigetoshi Kamada, general manager at the research department of Tachibana Securities.

New Strong Sell Stocks for August 25th
25 Aug, 2021 Yahoo! Finance

BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
11 Aug, 2021 FinancialContent

On Wednesday morning, 67 companies achieved new lows for the year. Areas of Significance: Grifols ...

Kamada (KMDA) Q2 Earnings and Revenues Miss Estimates
11 Aug, 2021 Yahoo! Finance

Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities
11 Aug, 2021 FinancialContent
Kamada's Earnings Outlook
10 Aug, 2021 FinancialContent

Kamada (NASDAQ:KMDA) unveils its next round of earnings this Wednesday, August 11. Get prepared with Benzinga's ultimate preview for ...

Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021
05 Aug, 2021 FinancialContent
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for
04 Aug, 2021 Yahoo! Finance

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Hedge Funds Are Selling Kamada Ltd (KMDA)
18 Jun, 2021 Yahoo! Finance

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children
02 Jun, 2021 FinancialContent
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
14 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Kamada (KMDA) Q1 Earnings Top Estimates
12 May, 2021 Yahoo! Finance

Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities
12 May, 2021 FinancialContent
Kamada Ltd. to Host Earnings Call
12 May, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / May 12, 2021 / Kamada Ltd. (NASDAQ:KMDA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 8:30 AM Eastern Time.

Earnings Scheduled For May 12, 2021
12 May, 2021 FinancialContent

Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for its first ...

Kamada Ltd (KMDA) is a NASDAQ Common Stock listed in , ,

970x250